论文信息 - Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? - 字舞流文

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

P. Fenaux | C. Gardin | C. Chomienne | S. Burcheri | J. Kiladjian | B. Cassinat | V. Beco | C. Laguillier

[1] T. Barbui,et al. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. , 2007, Haematologica.

[2] P. Campbell,et al. The myeloproliferative disorders. , 2006, The New England journal of medicine.

[3] P. Fenaux,et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders , 2006, Leukemia.

[4] J. Thiele,et al. Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders. , 2006, Seminars in thrombosis and hemostasis.

[5] A. Tefferi. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. , 2006, Hematology. American Society of Hematology. Education Program.

[6] A. Tefferi. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. , 2006, Hematology. American Society of Hematology. Education Program.

[7] P. Campbell,et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study , 2005, The Lancet.

[8] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[9] J. Spivak,et al. Polycythemia vera: myths, mechanisms, and management. , 2002, Blood.